http://medwatch.dk/secure/Medicinal___Biotek/article4974637.ece

 

Det er meget glædeligt at abbott nu går igang med deres phase IIb studie med ABT-719. Hvis stoffet godkendes i sidste ende, er Zealand Pharma berettiget til royalty af det globale salg på ca. 5 %:

About Investor1989

Investor in stocks in about 5 years with some very good profits. Focusing on Biotech and Value stocks. Active investor...

 

What do you say?

Set your Twitter account name in your settings to use the TwitterBar Section.